Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Therapy for Childhood Extracranial Germ Cell Tumors
NCT00053352Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Nov 2003
- Primary completion
- Oct 2013
- Modality
- Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label trial of Cisplatin micelle injection (HA132), etoposide and bleomycin in extracranial germ cell tumor (EGCT) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Event-Free Survival at 3 years and Overall Survival at 3 years. Started Nov 2003; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)etoposidebleomycin
03
Conditions
extracranial germ cell tumor (EGCT)
Beyond the preview
Go deeper on NCT00053352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053352.